(Q39206045)

https://api.crossref.org/works/10.1007/BF00426893

10 September 2017

Tardive dyskinesia and psychotropic drug history (English)

1 reference

29 March 2022

1 reference

1 reference

https://api.crossref.org/works/10.1007/BF00426893

29 March 2022

author name string

G. M. Simpson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A28544

29 March 2022

E. Varga

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A28544

29 March 2022

J. H. Lee

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A28544

29 March 2022

B. Zoubok

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A28544

29 March 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=28544

29 March 2022

publication date

1 July 1978

1 reference

10 September 2017

6 July 1978

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=28544

29 March 2022

number of pages

8

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

10 September 2017

58

1 reference

10 September 2017

2

1 reference

10 September 2017

117-124

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00426893

10 September 2017

0 references

cites work

High Doses of Trifluperazine and Tardive Dyskinesia

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF00426893

Tardive dyskinesia and drug therapy in geriatric patients.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF00426893

Tardive Dyskinesia: Its Relation to Neuroleptic and Antiparkinson Drugs

21 January 2018

1 reference

12 December 2020

Persistent Dyskinesia

1 reference

12 December 2020

Drug variables in the etiology of tardive dyskinesia application of discriminant function analysis

1 reference

12 December 2020

AN APPARENTLY IRREVERSIBLE SYNDROME OF ABNORMAL MOVEMENTS FOLLOWING PHENOTHIAZINE MEDICATION

1 reference

12 December 2020

The Significance of Brain Damage in Persistent Oral Dyskinesia

1 reference

12 December 2020

Extrapyramidal disorders after prolonged phenothiazine therapy

1 reference

12 December 2020

Persistent oral dyskinesia in female mental hospital patients.

1 reference

12 December 2020

Comparative Analysis of Persistent Dyskinesias of Long-Term Usage With Neuroleptics in France and in Japan

1 reference

12 December 2020

The prevalence of tardive dyskinesias in mental hospital patients.

1 reference

12 December 2020

NEUROLOGICAL SYMPTOMS IN PHARMACOTHERAPY OF PSYCHOSES

1 reference

12 December 2020

Antiparkinson drugs as causal agents in tardive dyskinesia

1 reference

12 December 2020

Epidemiology of tardive dyskinesia Part I

1 reference

12 December 2020

Problems in the evaluation of the optimal dose of a phenothiazine (butaperazine).

1 reference

12 December 2020

Letter: Deanol for tardive dyskinesia

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00426893

1 reference

10 September 2017

1 reference